| iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research | 2020 | April 15, 2020 | 2020 |
| iCo Therapeutics Announces Leadership Changes | 2020 | March 9, 2020 | 2020 |
| iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B | 2020 | February 25, 2020 | 2020 |
| iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing & Follow Up | 2020 | February 10, 2020 | 2020 |
| iCo Therapeutics Announces Option Grants | 2020 | January 10, 2020 | 2020 |
| iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects | 2019 | December 24, 2019 | 2019 |
| iCo Therapeutics Engages Ora for iCo-008 Ophthalmic Strategy and Pre Phase II FDA Meeting | 2019 | December 11, 2019 | 2019 |
| iCo Therapeutics Announces Dosing of First Full Cohort in Second Oral Amphotericin B Study | 2019 | December 9, 2019 | 2019 |
| iCo Therapeutics Announces Third Quarter 2019 Financial Results | 2019 | December 2, 2019 | 2019 |
| Alexion Pharmaceuticals – iCo’s New Partner for the Development and Commercialization of iCo-008 | 2019 | November 25, 2019 | 2019 |
| iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities | 2019 | October 28, 2019 | 2019 |
| iCo Therapeutics Inc. Provides a Corporate Update | 2019 | October 22, 2019 | 2019 |
| iCo Therapeutics Announces Second Quarter 2019 | 2019 | August 28, 2019 | 2019 |
| iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement | 2019 | August 19, 2019 | 2019 |
| iCo Therapeutics Provides Corporate Update | 2019 | August 6, 2019 | 2019 |
| iCo Therapeutics Announces AGM Voting Results | 2019 | June 28, 2019 | 2019 |
| iCo Therapeutics Announces First Quarter 2019 Financial Results | 2019 | May 30, 2019 | 2019 |
| iCo Therapeutics Announces 2018 Year End Financial | 2019 | April 30, 2019 | 2019 |
| iCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement | 2019 | March 5, 2019 | 2019 |
| iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement | 2019 | February 25, 2019 | 2019 |
| iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008) | 2019 | February 19, 2019 | 2019 |
| iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN | 2019 | February 19, 2019 | 2019 |
| iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement | 2019 | February 11, 2019 | 2019 |
| iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000 | 2019 | February 7, 2019 | 2019 |
| iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000 | 2019 | January 31, 2019 | 2019 |
| iCo Therapeutics Announces Third Quarter 2018 Financial Results And Corporate Update | 2018 | November 29, 2018 | 2018 |
| iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study | 2018 | November 15, 2018 | 2018 |
| iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board | 2018 | October 23, 2018 | 2018 |
| iCo Therapeutics Provides Corporate Update | 2018 | October 2, 2018 | 2018 |
| iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference | 2018 | September 6, 2018 | 2018 |
| iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update | 2018 | August 29, 2018 | 2018 |
| iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials – Phase 1 Oral Amphotericin B | 2018 | July 16, 2018 | 2018 |
| iCo Therapeutics Announces Positive Clinical Outcome – Primary Endpoint Met in Phase 1 Oral Amphotericin B Study | 2018 | June 27, 2018 | 2018 |
| iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment | 2018 | June 20, 2018 | 2018 |
| iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial | 2018 | May 30, 2018 | 2018 |
| iCo Therapeutics Announces Year End 2017 Financial Results | 2018 | April 24, 2018 | 2018 |
| iCo Therapeutics Announces Major Milestone – Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study | 2018 | April 18, 2018 | 2018 |
| iCo Therapeutics Announces Third Quarter 2017 Financial Results | 2017 | November 28, 2017 | 2017 |
| iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study | 2017 | November 22, 2017 | 2017 |
| iCo Therapeutics Announces Upcoming Presentations and Meetings | 2017 | September 7, 2017 | 2017 |
| iCo Therapeutics Announces Second Quarter 2017 Financial Results | 2017 | August 29, 2017 | 2017 |
| iCo Therapeutics Inc. Approves Advance Notice Policy | 2017 | August 4, 2017 | 2017 |
| iCo Therapeutics Announces Election of Directors | 2017 | June 30, 2017 | 2017 |
| iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset | 2017 | June 15, 2017 | 2017 |
| iCo Therapeutics Announces Positive Oral Amphotericin Study | 2017 | June 12, 2017 | 2017 |
| iCo Therapeutics Announces First Quarter 2017 Financial Results | 2017 | May 24, 2017 | 2017 |
| iCo Therapeutics Announces Year End 2016 Financial Results | 2017 | April 19, 2017 | 2017 |
| iCo Therapeutics Inc. Announces No Material Change | 2017 | March 13, 2017 | 2017 |
| CLARIFICATION iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program | 2016 | November 28, 2016 | 2016 |
| iCo Therapeutics Announces Third Quarter 2016 Financial Results | 2016 | November 24, 2016 | 2016 |
| iCo Therapeutics Announces World Wide Exclusive Option and EU License Rights with Laboratorios SALVAT for Novel Glaucoma Asset | 2016 | November 15, 2016 | 2016 |
| iCo Therapeutics Announces Second Quarter 2016 Financial Results | 2016 | August 19, 2016 | 2016 |
| iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders | 2016 | June 27, 2016 | 2016 |
| iCo Therapeutics Announces Year End 2015 Financial Results | 2016 | April 14, 2016 | 2016 |
| iCo Therapeutics Inc. Announces Grant of Stock Options and Recent CEO Share Purchases | 2016 | February 17, 2016 | 2016 |
| iCo Strategic Reorganization | 2016 | January 18, 2016 | 2016 |
| iCo Therapeutics Announces Changes to Board of Directors | 2015 | December 24, 2015 | 2015 |
| iCo Therapeutics Announces Third Quarter 2015 Financial Results | 2015 | November 24, 2015 | 2015 |
| iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program | 2015 | October 26, 2015 | 2015 |
| iCo Therapeutics Announces Second Quarter 2015 Financial Results | 2015 | August 26, 2015 | 2015 |
| iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders | 2015 | June 26, 2015 | 2015 |
| iCo Therapeutics Announces First Quarter 2015 Financial Results | 2015 | May 28, 2015 | 2015 |
| iCo Therapeutics Announces Year End 2014 Financial Results | 2015 | April 27, 2015 | 2015 |
| iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update | 2014 | November 28, 2014 | 2014 |
| iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS | 2014 | November 4, 2014 | 2014 |
| iCo Therapeutics Announces Advancement of Oral Amphotericin B Program | 2014 | October 22, 2014 | 2014 |
| iCo Therapeutics Announces Second Quarter 2014 Financial Results | 2014 | August 29, 2014 | 2014 |
| iCo Therapeutics Announces Positive Oral Amphotericin B Study Results | 2014 | August 19, 2014 | 2014 |
| iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders | 2014 | June 30, 2014 | 2014 |
| iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema | 2014 | June 9, 2014 | 2014 |
| iCo Therapeutics Announces First Quarter 2014 Financial Results | 2014 | May 29, 2014 | 2014 |
| iCo Therapeutics Announces Poster Presentation at ARVO | 2014 | April 29, 2014 | 2014 |
| iCo Therapeutics Announces Year End 2013 Financial Results | 2014 | April 24, 2014 | 2014 |
| iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study | 2014 | March 5, 2014 | 2014 |
| iCo Therapeutics Announces DTC Approval | 2014 | February 25, 2014 | 2014 |
| iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing | 2014 | January 27, 2014 | 2014 |
| iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing | 2014 | January 22, 2014 | 2014 |
| iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering | 2014 | January 21, 2014 | 2014 |
| iCo Therapeutics Begins Trading on the OTCQX Marketplace | 2013 | December 20, 2013 | 2013 |
| iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B | 2013 | December 12, 2013 | 2013 |
| iCo Therapeutics To Present At Jefferies Ophthalmic Therapeutic Summit | 2013 | December 5, 2013 | 2013 |
| iCo Therapeutics Announces Third Quarter 2013 Financial Results | 2013 | November 27, 2013 | 2013 |
| iCo Therapeutics to Present at the 6th Annual LD MICRO | 2013 | November 21, 2013 | 2013 |
| iCo Therapeutics Announces Warrant Exercise | 2013 | November 13, 2013 | 2013 |
| iCo Therapeutics to Present at the Ophthalmology Innovation Summit | 2013 | November 7, 2013 | 2013 |
| iCo Therapeutics Grants Options to a Director | 2013 | September 5, 2013 | 2013 |
| iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference | 2013 | September 4, 2013 | 2013 |
| iCo Therapeutics Announces Second Quarter 2013 Financial Results | 2013 | August 26, 2013 | 2013 |
| iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema | 2013 | June 18, 2013 | 2013 |
| iCo Therapeutics Announces First Quarter 2013 Financial Results | 2013 | May 29, 2013 | 2013 |
| iCo Therapeutics Announces Director Election Results from its Annual General Meeting of Shareholders | 2013 | May 24, 2013 | 2013 |
| iCo Therapeutics Closes $3.4 Million Financing | 2013 | May 21, 2013 | 2013 |
| iCo Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference | 2013 | May 15, 2013 | 2013 |
| iCo Therapeutics to Raise $3.2 Million | 2013 | May 10, 2013 | 2013 |
| iCo Therapeutics Announces Overnight Marketed Equity Offering | 2013 | May 9, 2013 | 2013 |
| iCo Therapeutics Announces Year End 2012 Financial Results | 2013 | April 25, 2013 | 2013 |
| iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 50 | 2013 | February 14, 2013 | 2013 |
| iCo Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference | 2013 | February 5, 2013 | 2013 |
| iCo Therapeutics Grants Options to Directors, Officers and Employees | 2013 | January 22, 2013 | 2013 |
| iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update | 2013 | January 3, 2013 | 2013 |
| iCo Therapeutics Announces Third Quarter 2012 Financial Results | 2012 | November 29, 2012 | 2012 |
| iCo Therapeutics’ Oral Amphotericin B Delivery System to be Presented at AAPS with Updated Patent Position | 2012 | October 12, 2012 | 2012 |
| iCo Therapeutics to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference | 2012 | September 4, 2012 | 2012 |
| iCo Therapeutics Announces Second Quarter 2012 Financial Results | 2012 | August 29, 2012 | 2012 |
| iCo Therapeutics Closes $2.55 Million Financing | 2012 | July 13, 2012 | 2012 |
| iCo Therapeutics to Raise $2.55 Million | 2012 | July 5, 2012 | 2012 |
| iCo Therapeutics Announces Overnight Marketed Equity Offering | 2012 | July 4, 2012 | 2012 |
| iCo Therapeutics receives funding from the Government of Canada for the pre-clinical and clinical development of its Oral Amphotericin B Delivery System for the treatment of HIV/AIDS | 2012 | May 31, 2012 | 2012 |
| iCo Therapeutics Announces First Quarter 2012 Financial Results | 2012 | May 30, 2012 | 2012 |
| iCo Therapeutics Announces Year End 2011 Financial Results | 2012 | April 13, 2012 | 2012 |
| iCo Therapeutics and JDRF Team Up to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema | 2012 | March 28, 2012 | 2012 |
| iCo Therapeutics CEO to Present at Retinal Physician Symposium 2012 | 2012 | March 27, 2012 | 2012 |
| iCo Therapeutics Appoints Douglas Janzen to Board of Directors | 2012 | March 5, 2012 | 2012 |
| iCo Therapeutics Retains Crescendo Communications | 2012 | January 17, 2012 | 2012 |
| iCo Therapeutics Announces Execution of Equity Line Facility Agreement | 2011 | December 4, 2011 | 2011 |
| iCo Therapeutics Announces Third Quarter 2011 Financial Results | 2011 | November 18, 2011 | 2011 |
| iCo Therapeutics Closes $1,115,000 Non-Brokered Private Placement | 2011 | November 2, 2011 | 2011 |
| iCo Therapeutics Oral Amphotericin B Delivery System to be Presented at AAPS | 2011 | October 24, 2011 | 2011 |
| iCo Therapeutics CEO to Present at the Ophthalmology Innovation Summit | 2011 | October 20, 2011 | 2011 |
| iCo Therapeutics Grants Options to Directors, Officers and Employees | 2011 | September 27, 2011 | 2011 |
| iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema | 2011 | September 26, 2011 | 2011 |
| iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference | 2011 | September 13, 2011 | 2011 |
| iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference | 2011 | September 13, 2011 | 2011 |
| iCo Therapeutics Announces Second Quarter 2011 Financial Results | 2011 | August 29, 2011 | 2011 |
| iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone | 2011 | August 15, 2011 | 2011 |
| iCo Therapeutics Announces Resignation of John Clement, Chief Technology and Development Officer and Director | 2011 | July 22, 2011 | 2011 |
| iCo Therapeutics Engages The Equicom Group | 2011 | July 19, 2011 | 2011 |
| iCo Therapeutics CMO to Present at The Drug Repositioning Conference | 2011 | July 12, 2011 | 2011 |
| iCo Therapeutics Announces First Quarter 2011 Financial Results | 2011 | June 29, 2011 | 2011 |
| iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals | 2011 | June 24, 2011 | 2011 |
| iCo Therapeutics CEO to Present & Participate in Panel at BioFinance 2011 | 2011 | May 31, 2011 | 2011 |
| iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance | 2011 | May 13, 2011 | 2011 |
| iCo Therapeutics Announces Year-End 2010 Financial Results | 2011 | April 29, 2011 | 2011 |
| iCo Therapeutics Inc. Secures $10 Million Equity Line Facility | 2011 | April 14, 2011 | 2011 |
| iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011 | 2011 | February 23, 2011 | 2011 |
| iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing | 2011 | February 22, 2011 | 2011 |
| iCo Therapeutics Extends Investor Relations Engagement with The Trout Group | 2010 | December 24, 2010 | 2010 |
| iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties | 2010 | December 8, 2010 | 2010 |
| iCo Therapeutics Reports Third Quarter 2010 Financial Results | 2010 | November 26, 2010 | 2010 |
| iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner | 2010 | October 13, 2010 | 2010 |
| iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status | 2010 | September 29, 2010 | 2010 |
| iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board | 2010 | September 22, 2010 | 2010 |
| iCo Therapeutics Announces Second Quarter 2010 Financial Results | 2010 | August 27, 2010 | 2010 |
| iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007 | 2010 | July 26, 2010 | 2010 |
| iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak | 2010 | May 28, 2010 | 2010 |
| iCo Therapeutics Announces First Quarter 2010 Financial Results | 2010 | May 26, 2010 | 2010 |
| iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-007 | 2010 | May 25, 2010 | 2010 |
| iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint | 2010 | May 17, 2010 | 2010 |
| iCo Therapeutics Announces Year-End 2010 Financial Results | 2011 | April 29, 2010 | 2011 |
| iCo Therapeutics Announces Year-End 2009 Financial Results | 2010 | April 29, 2010 | 2010 |
| iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing | 2010 | April 28, 2010 | 2010 |
| iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 2010 | 2010 | April 22, 2010 | 2010 |
| iCo Therapeutics Inc. Secures $10 Million Equity Line Facility | 2011 | April 14, 2010 | 2011 |
| iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award | 2010 | April 12, 2010 | 2010 |
| iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011 | 2011 | February 23, 2010 | 2011 |
| iCo-007 for Diabetic Macular Edema to be Presented at Angiogenesis 2010: Clinical Trials | 2010 | February 19, 2010 | 2010 |
| iCo Therapeutics Announces Exercise of Warrants | 2010 | February 10, 2010 | 2010 |
| iCo Therapeutics Grants Options to Directors, Officers and Employees | 2009 | December 30, 2009 | 2009 |
| iCo Therapeutics Provides Phase 1 DME Clinical Trial Update and Phase 2 Trial Guidance | 2009 | December 11, 2009 | 2009 |
| iCo Therapeutics iCo-007 Overview to be Presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics | 2009 | December 3, 2009 | 2009 |
| iCo Therapeutics Q3 2009 Financial Results | 2009 | November 26, 2009 | 2009 |
| iCo Therapeutics Completes Final Tranche of $4,000,000 Brokered Private Placement | 2009 | November 20, 2009 | 2009 |
| iCo Therapeutics Completes First Tranche of Brokered Private Placement | 2009 | October 30, 2009 | 2009 |
| iCo Therapeutics Announces $4,000,000 Brokered Private Placement | 2009 | October 20, 2009 | 2009 |
| iCo Therapeutics Signs Collaboration Agreement with The Consortium for Parasitic Drug Development | 2009 | September 24, 2009 | 2009 |
| iCo Therapeutics Q2 2009 Financial Results | 2009 | August 21, 2009 | 2009 |
| iCo Therapeutics Appoints Infectious Disease MD to Scientific Advisory Board | 2009 | July 21, 2009 | 2009 |
| iCo Therapeutics Closes Non-Brokered Private Placement | 2009 | July 16, 2009 | 2009 |
| iCo Therapeutics Diabetic Macular Edema Clinical Trial Update | 2009 | July 7, 2009 | 2009 |
| iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment | 2009 | July 2, 2009 | 2009 |
| iCo Therapeutics Positive Oral Amphotericin B Data Published in the Journal of Infectious Diseases | 2009 | June 25, 2009 | 2009 |
| Shareholders Approve All Resolutions at iCo Therapeutics Annual General Meeting | 2009 | June 8, 2009 | 2009 |
| iCo Therapeutics Q1 2009 Financial Results | 2009 | May 29, 2009 | 2009 |
| iCo Therapeutics Year-End 2008 Financial Results | 2009 | April 30, 2009 | 2009 |
| iCo Therapeutics to Present at BioFinance 2009 | 2009 | April 29, 2009 | 2009 |
| iCo Therapeutics Oral Anti-Parasitic Drug to be Presented at Global Health Symposia | 2009 | March 23, 2009 | 2009 |
| iCo Therapeutics iCo-007 Second Cohort Results to be Presented at Cleveland Clinic Ocular Conference | 2009 | March 17, 2009 | 2009 |
| iCo Therapeutics Grants Options to New Directors | 2009 | February 20, 2009 | 2009 |
| iCo Therapeutics iCo-007 Results to be Presented at Prestigious Ocular Conference | 2009 | February 19, 2009 | 2009 |
| iCo Therapeutics Oral Amphotericin B Published in Leading Journal | 2009 | February 18, 2009 | 2009 |
| iCo Therapeutics Closes $1.3 Million Private Placement | 2009 | February 9, 2009 | 2009 |
| iCo Therapeutics Closes First Tranche of Non-Brokered Private Placement | 2009 | January 30, 2009 | 2009 |
| iCo Therapeutics Oral Amphotericin B Poster at AAPS | 2008 | November 18, 2008 | 2008 |
| iCo Therapeutics Third Quarter Financial Results | 2008 | November 17, 2008 | 2008 |
| iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis | 2008 | November 7, 2008 | 2008 |
| iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results | 2008 | October 9, 2008 | 2008 |
| iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner | 2008 | October 1, 2008 | 2008 |
| iCo Therapeutics to Present at BioContact Québec | 2008 | September 29, 2008 | 2008 |
| iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema) | 2008 | September 22, 2008 | 2008 |
| iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial | 2008 | September 4, 2008 | 2008 |
| iCo Therapeutics Second Quarter Financial Results | 2008 | August 28, 2008 | 2008 |
| iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board | 2008 | July 8, 2008 | 2008 |
| iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results | 2008 | June 26, 2008 | 2008 |
| iCo Therapeutics Closes $1,140,450 Financing | 2008 | June 9, 2008 | 2008 |
| iCo Therapeutics Announces $1,140,450 Financing | 2008 | June 2, 2008 | 2008 |
| iCo Therapeutics First Quarter Financial Results | 2008 | May 30, 2008 | 2008 |
| iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B) | 2008 | May 7, 2008 | 2008 |
| iCo Therapeutics to Present at BioFinance 2008 | 2008 | May 5, 2008 | 2008 |
| iCo Therapeutics Year-End 2007 Financial Results | 2008 | April 28, 2008 | 2008 |
| iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO | 2008 | April 25, 2008 | 2008 |
| iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting | 2008 | April 21, 2008 | 2008 |
| iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal | 2008 | March 17, 2008 | 2008 |
| iCo Therapeutics Provides iCo-008 Phase II Clinical Update | 2008 | March 10, 2008 | 2008 |
| iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference | 2008 | February 27, 2008 | 2008 |
| iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update | 2008 | January 21, 2008 | 2008 |
| iCo Therapeutics Inc. and Beanstalk Capital Ltd. Announce Completion of Arrangement | 2007 | December 31, 2007 | 2007 |
| Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement | 2007 | October 31, 2007 | 2007 |
| Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. | 2007 | October 16, 2007 | 2007 |
| Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007 | 2007 | October 9, 2007 | 2007 |
| iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema | 2007 | January 22, 2007 | 2007 |
| iCo Therapeutics Announces Licensing Deal | 2007 | January 10, 2007 | 2007 |
| Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo | 2007 | January 8, 2007 | 2007 |
